Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis.

MLA

Lio, Peter A., et al. “Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis.” Dermatology & Therapy, vol. 14, no. 7, July 2024, pp. 1929–43. EBSCOhost, https://doi.org/10.1007/s13555-024-01199-9.

APA

Lio, P. A., Armstrong, A., Gutermuth, J., Nosbaum, A., Sofen, H., Gil, E. G., Casillas, M., Chen, S., Sun, L., Pierce, E., Elmaraghy, H., Dawson, Z., & Torres, T. (2024). Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis. Dermatology & Therapy, 14(7), 1929–1943. https://doi.org/10.1007/s13555-024-01199-9

Chicago

Lio, Peter A., April Armstrong, Jan Gutermuth, Audrey Nosbaum, Howard Sofen, Esther Garcia Gil, Marta Casillas, et al. 2024. “Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis.” Dermatology & Therapy 14 (7): 1929–43. doi:10.1007/s13555-024-01199-9.